指南与共识消化内镜消化道肿瘤与早癌

AGA临床实践更新:非壶腹部十二指肠病变专家综述

AGA Clinical Practice Update on Nonampullary Duodenal Lesions: Expert Review.
指南 / 共识 · Gastroenterology · 2024-11-16

非壶腹部十二指肠息肉见于高达5%的上消化道内镜检查,多数为偶然发现的无症状病变,腺瘤约占10%-20%。多数国际指南推荐所有十二指肠腺瘤应考虑内镜下切除,但前瞻性研究中不良事件率近15%,主要为出血和穿孔,且监测中局部复发率较高。本AGA临床实践更新专家综述阐述了十二指肠息肉的风险分层、内镜下切除与监测方法及并发症管理。

要点

  • 所有十二指肠息肉应记录大小、巴黎分型、可疑组织层次、十二指肠部位(D1-4)及与主乳头的关系。
  • 发现十二指肠腺瘤时,若近3年内未行高质量结肠镜检查,应行结肠镜检查。
  • 完全切除的十二指肠腺瘤初始内镜监测间隔为6个月。

核心结论

  • 十二指肠腺瘤应考虑内镜下切除,但需结合患者合并症和预期寿命个体化决策,并注意切除相关并发症风险。

研究设计与样本

  • 美国胃肠病协会(AGA)临床实践更新委员会与AGA理事会委托并批准的专家综述,基于已发表文献综述和专家意见,未进行系统评价,最佳实践建议未对证据质量或推荐强度进行正式评级。

主要发现

  • 非壶腹部十二指肠息肉见于高达5%的上消化道内镜检查,多数为无症状患者偶然发现,腺瘤估计占10%-20%。
  • 前瞻性研究中十二指肠腺瘤内镜下切除的不良事件率近15%,主要为出血和穿孔,监测中局部复发率较高。
  • 病变>3 cm时出血风险>25%,可能危及生命并伴血流动力学不稳定,但复苏后内镜下止血通常有效。

关键数值与推荐

  • 最佳实践建议1:非肿瘤性十二指肠病变(如胃小凹上皮化生和胃异位)可能模仿肿瘤性腺瘤性病变,需仔细光学评估和病理相关性以排除异型增生;无异性增生的病变除非有症状或出血,否则无需内镜下切除。
  • 最佳实践建议4:发现十二指肠腺瘤时,若近3年内未行高质量结肠镜检查,应行结肠镜检查。
  • 最佳实践建议5:不建议对散发性或非散发性十二指肠腺瘤患者常规行小肠检查(即胶囊内镜);Peutz-Jeghers综合征患者定期胶囊内镜小肠检查可能有益。
  • 最佳实践建议8:对<20 mm的平坦十二指肠腺瘤,分块冷圈套切除可降低术后出血风险,有效且复发风险极低;合并症患者<20 mm平坦非隆起病变可考虑冷圈套切除。
  • 最佳实践建议9:>20 mm或伴大巴黎Is亚型成分的十二指肠腺瘤应采用传统热圈套内镜下黏膜切除术;内镜下黏膜切除术后切缘热消融以降低复发风险至<2%-5%安全有效,应考虑采用。

临床怎么用

  • 非肿瘤性十二指肠病变无需内镜下切除,除非有症状或出血;所有散发性十二指肠腺瘤应考虑内镜下切除,但需结合合并症和预期寿命个体化决策。
  • 十二指肠腺瘤>20 mm或伴大巴黎Is亚型成分采用传统热圈套内镜下黏膜切除术,切缘热消融可考虑;<20 mm平坦病变可采用冷圈套切除。
  • 内镜医师应了解十二指肠息肉切除术后出血风险高于消化道其他部位,通常发生于术后48小时内,风险与病变大小成比例。
  • 完全切除的十二指肠腺瘤初始内镜监测间隔为6个月,复发常伴瘢痕且常规圈套切除困难,可能需撕脱技术。

局限性

  • 未进行系统评价,最佳实践建议未对证据质量或推荐强度进行正式评级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: Nonampullary duodenal polyps are found in up to 5% of all upper endoscopies; the vast majority are identified incidentally in asymptomatic patients. Although most are benign, adenomas are estimated to account for 10%-20% of these lesions. Most international guidelines recommend that all duodenal adenomas should be considered for endoscopic resection; this may be associated with a near 15% adverse event rate (predominantly bleeding and perforation) in prospective studies, with substantial local recurrence on surveillance. The aim of this American Gastroenterological Association (AGA) Clinical Practice Update Expert Review was to describe how individuals should be evaluated and risk-stratified for duodenal polyps, the best approaches to endoscopic resection and surveillance, and management of complications, highlighting opportunities for future research to fill gaps in the existing literature. METHODS: This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Gastroenterology. These Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these Best Practice Advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: Non-neoplastic duodenal lesions (eg, metaplastic foveolar epithelium and gastric heterotopia) may mimic neoplastic adenomatous pathology. Careful optical evaluation and pathologic correlation may be necessary to exclude dysplasia. Nondysplastic lesions do not require endoscopic resection unless they are symptomatic or bleeding. BEST PRACTICE ADVICE 2: Ideal duodenal endoscopic inspection includes identification of the major and minor papilla with photodocumentation to ensure no involvement by the lesion. Adding a clear distal attachment device to a forward-viewing gastroscope improves visualization of the papilla and the medial wall. A side-viewing duodenoscope should be used when the major and minor papilla are not visible with the gastroscope and for most lesions on the medial wall of the duodenum within 5 cm of the ampulla. BEST PRACTICE ADVICE 3: All duodenal polyps should be described according to their size, Paris morphology, suspected histologic layer of origin (mucosal lesion or subepithelial lesion), duodenal location (D1-4) and orientation (anterior, posterior, medial, or lateral wall), and proximity/relationship to the major papilla to facilitate therapeutic planning and subsequent surveillance. BEST PRACTICE ADVICE 4: Given the high frequency of concomitant colonic adenomas in patients with duodenal adenomas, on identification of a duodenal adenoma, a colonoscopy should be performed if a high-quality examination has not been performed in the last 3 years. BEST PRACTICE ADVICE 5: Routine small bowel investigation (ie, capsule endoscopy) is not advised in patients with sporadic and nonsporadic duodenal adenomas. Periodic small bowel inspection with capsule endoscopy may be of benefit in patients with Peutz-Jeghers syndrome. BEST PRACTICE ADVICE 6: Definitive treatment of duodenal adenomas by endoscopic resection is less morbid, resource-intensive, and expensive than surgery and is therefore the preferred treatment option. BEST PRACTICE ADVICE 7: Due to the risk of malignant transformation, all sporadic duodenal adenomas should be considered for endoscopic resection. However, in comparison with colonic adenomas, the time course to malignant transformation may be more prolonged, and the risk of resection-related morbidity much greater. Therefore, the comorbidities and anticipated longevity of the patient must be carefully factored into the decision-making process. BEST PRACTICE ADVICE 8: The approach to endoscopic duodenal resection (ie, hot vs cold and conventional vs underwater endoscopic mucosal resection) should be individualized to reduce bleeding risk, based on lesion size, morphology, patient comorbidities, and endoscopist comfort level with specific techniques. Piecemeal cold snare resection for flat duodenal adenomas mitigates postprocedural bleeding risk and, for lesions <20 mm, is effective and carries a minimal risk of recurrence. In patients with comorbidities with flat nonbulky lesions measuring < 20 mm, cold snare resection can be considered. BEST PRACTICE ADVICE 9: Currently, duodenal adenomas >20 mm or with large Paris subtype Is components should be removed by conventional hot snare endoscopic mucosal resection. Thermal ablation of the post-endoscopic mucosal resection margin to mitigate the risk of recurrence to <2%-5% is safe and effective and should be considered. BEST PRACTICE ADVICE 10: Endoscopists performing duodenal polyp resection should be aware of the increased risk of postprocedural bleeding (compared with elsewhere in the gastrointestinal tract), which usually occurs in the first 48 hours after the procedure, with the risk proportional to the lesion size. For lesions >3 cm, bleeding risk is >25% and may be life-threatening and associated with hemodynamic compromise; however, after resuscitation, endoscopic hemostasis is generally effective. BEST PRACTICE ADVICE 11: Evaluation of the postpolypectomy/endoscopic mucosal resection defect is critical to identify concerns for postprocedural duodenal perforation, which, if unrecognized and left untreated, may be life-threatening and often mandates surgery. BEST PRACTICE ADVICE 12: Initial endoscopic surveillance for a completely resected duodenal adenoma should be undertaken at an interval of 6 months. Although usually diminutive, recurrence is often scarred and not amenable to conventional snare resection and may require avulsion techniques to achieve cure. BEST PRACTICE ADVICE 13: Nonampullary duodenal adenomas associated with familial adenomatous polyposis should be considered for endoscopic resection based on size (≥1 cm), morphologic characteristics, advanced histology (ie, high-grade dysplasia), and/or based on Spiegelman criteria.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Bourke MJ, Lo SK, Buerlein RCD, et al. AGA Clinical Practice Update on Nonampullary Duodenal Lesions: Expert Review. Gastroenterology. 2024. PMID: 39545885. doi:10.1053/j.gastro.2024.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。